SCM
VTYX

Suvretta Capital Management’s Ventyx Biosciences VTYX Stock Holding History

Suvretta Capital Management’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-186,400
Closed -$6.11M – 113
2022
Q4 		$6.11M Hold
186,400
– – 0.26% 55
2022
Q3 		$6.51M Buy
+186,400
New +$4.13M 0.27% 52

Other funds holding VTYX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Suvretta Capital Management's VTYX Position: Q1 2023 in Review

Suvretta Capital Management sold out of Ventyx Biosciences (VTYX) in Q1 2023, closing a stake of 186,400 shares — an estimated $6.11M sold.

Suvretta Capital Management first reported a position in VTYX in Q3 2022 and held it in 2 quarters. The position peaked at $6.51M in Q3 2022. 146 funds tracked by Wall St. Rank hold VTYX as of Q1 2023.

  • Suvretta Capital Management reported no remaining Ventyx Biosciences position as of Q1 2023 after selling out during the quarter.
  • Suvretta Capital Management sold 186,400 Ventyx Biosciences shares in Q1 2023, an estimated $6.11M.
  • Suvretta Capital Management first reported a position in Ventyx Biosciences in Q3 2022 and held it in 2 quarters.
  • Suvretta Capital Management's Ventyx Biosciences position peaked at $6.51M in Q3 2022.
  • 146 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2023.

Based on Suvretta Capital Management's 13F filing for Q1 2023, filed 15 May 2023.